Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

In the alternative pathway, C3b binds to Factor B. Factor D releases Factor Ba from Factor B bound to C3b. The complex of C3b (2)Bb is a protease which cleaves C5 into C5b and C5a. C5 convertase is ...

Scientists have uncovered an alternative mechanism, triggered by an immune cell receptor, for activating the release of pro-inflammatory proteins during infection. The finding adds to understanding ...